Efficacy and Safety of IQP-VV-102 in Weight Management

InQpharm

Status and phase: Completed; Phase 3

Conditions: Overweight; Obesity

Treatments: Dietary Supplement: IQP-VV-102; Other: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT01681069

INQ/009712

Details and patient eligibility

About

Subjects are randomized to either IQP-VV-102 or a matching placebo. Over 12 weeks, the subjects' body weight, body fat and safety parameters are monitored

Enrollment: 120 patients

Sex: All

Ages: 18 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Age 18 to 60 years
• 25 kg/m2 ≤ BMI ≤ 35 kg/m2
• Written informed consent

Exclusion criteria

• Known sensitivity to sources of the active ingredients and excipients
• Pregnancy or nursing
• Inability to comply with study requirements, e.g. due to language difficulties
• Participation in another study during the last 30 days of the screening visit

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

120 participants in 2 patient groups, including a placebo group

IQP-VV-102

Active Comparator group

Description:

2 tablets twice a day

Treatment:

Dietary Supplement: IQP-VV-102

Placebo

Placebo Comparator group

Description:

2 tablets twice a day

Treatment:

Other: Placebo